Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C

IMPORTANCE: Recent reports based on the US Food and Drug Administration’s voluntary Adverse Events Reporting System raised questions about the safety of direct-acting antivirals (DAAs) for treatment of the hepatitis C virus (HCV). OBJECTIVE: To assess the rates of adverse events in patients with HCV...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:JAMA Netw Open
Main Authors: McGlynn, Elizabeth A., Adams, John L., Kramer, Jason, Sahota, Amandeep K., Silverberg, Michael J., Shenkman, Elizabeth, Nelson, David R.
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2019
Teme:
Original Investigation
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6563580/
https://ncbi.nlm.nih.gov/pubmed/31173117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2019.4765
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki